Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors

November 7th 2024

Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.

Enfortumab Vedotin Plus Pembrolizumab Leads to Shifts in Frontline Metastatic Urothelial Cancer Management

November 7th 2024

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

November 6th 2024

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management

November 6th 2024

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

November 6th 2024

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphoma

November 5th 2024

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

November 5th 2024

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

(Z)-endoxifen Reduces MBD, Is Well Tolerated in Premenopausal Women Screened for Breast Cancer

November 5th 2024

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.

FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 5th 2024

The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

November 4th 2024

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Regorafenib Provides Modest Survival Benefit in Refractory Advanced Gastric/GEJ Cancer

November 4th 2024

Regorafenib improved overall survival vs placebo in refractory advanced gastric or gastroesophageal junction cancer.

Continued Development of RAS Inhibitors Leads the Charge in Pancreatic Cancer Research

November 4th 2024

Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.

BXQ-350 Is Well Tolerated, Shows Clinical Activity in Advanced Solid Tumors

November 4th 2024

BXQ-350 was well tolerated and generated clinical activity in patients with advanced solid tumors.

Lasofoxifene Suppresses Ki-67 Expression in HR+/HER2– Early-Stage Breast Cancer

November 4th 2024

Lasofoxifene was well tolerated and had early activity signals in patients with HR-positive, HER2-negative, locally advanced breast cancer.

Neoadjuvant SHR-A1811 Plus Pyrotinib Shows Preliminary Efficacy, Safety in HER2+ Breast Cancer

November 4th 2024

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide-Refractory Myeloma

November 1st 2024

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer

November 1st 2024

A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.

Ameluz-PDT Leads to Target Lesion Clearance in Superficial Basal Cell Carcinoma

November 1st 2024

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

Prevention and Early Recognition of Veno-Occlusive Disease Is Key to Reducing Post-Transplant Mortality

November 1st 2024

Marc J. Braunstein, MD, PhD, discusses the diagnosis, prevention, and treatment of patients with veno-occlusive disease post-transplant.

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

October 31st 2024

Dr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.